Physician profile
Dylan Koenig
NPI 1780156232
$3,458.38
in general payments reported to CMS, 2019-2025
27 companies · $847 in 2025
The $847 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $127 · 2022: $495 · 2023: $1,025 · 2024: $964 · 2025: $847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,787 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,787.12 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,367.23 | 2021-2025 | |
| Pfizer INC. | $298.81 | 2023-2025 | |
| Glaxosmithkline, LLC. | $220.06 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $196.29 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $183.15 | 2021-2025 | Austedo, Austedo Xr, Ajovy |
| Astrazeneca Pharmaceuticals LP | $133.80 | 2021-2023 | Farxiga |
| Amgen INC. | $128.99 | 2022-2025 | Repatha, Otezla, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $119.28 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $101.60 | 2021-2025 | Capvaxive, Gardasil 9, Vaxelis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.98 | 2022-2025 | Jardiance |
| Vertex Pharmaceuticals Incorporated | $79.55 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $72.18 | 2022 | |
| Novo Nordisk INC | $67.95 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Averitas Pharma INC. | $65.96 | 2024 | Qutenza |
| Exact Sciences Corporation | $46.81 | 2025 | The Cologuard Plus Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $43.78 | 2024-2025 | Mounjaro, Zepbound |
| Eisai INC. | $37.39 | 2021 | |
| Lundbeck LLC | $35.41 | 2024-2025 | Vyepti, Rexulti |
| Novartis Pharmaceuticals Corporation | $32.12 | 2021-2022 | |
| Dexcom, INC. | $18.28 | 2024 | Dexcom G6 Transmitter |
| Medline Industries LP | $17.86 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $17.53 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.90 | 2022 | |
| Indivior INC. | $16.40 | 2025 | Sublocade |
| Axsome Therapeutics, INC. | $15.46 | 2025 | Auvelity |
| Gilead Sciences, INC. | $13.76 | 2024 | |
| Allergan, INC. | $11.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dylan Koenig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.